Cambridge: AstraZeneca has announced that Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder ...

1 Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China 2 School of Mathematics and Statistics, Central South University, Changsha, Hunan, China ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) announced today that its drug Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as a treatment for adult patients with ...

The CHMP recommended the approval of Imfinzi in combination with gemcitabine and cisplatin as a neoadjuvant treatment for muscle-invasive bladder cancer (MIBC), followed by Imfinzi as monotherapy ...

AstraZeneca received a positive recommendation from the European Medicines Agency for its cancer therapy Imfinzi, marking a significant advancement in its oncology portfolio. Despite this ...

(Alliance News) - AstraZeneca PLC on Tuesday said its Imfinzi, or durvalumab, therapy has been recommended for approval in the EU for the treatment of muscle-invasive bladder cancer. The Cambridge ...

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that its Imfinzi (durvalumab) has been recommended for approval in the European Union to treat muscle-invasive ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) announced today that its drug Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as a treatment for adult patients with ...